(Q33359798)

26 July 2017

Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

Mattheos Bobos

9

0 references

George Fountzilas

18

object named as

George Fountzilas

1 reference

26 July 2017

3

Eleni Vrettou

1 reference

26 July 2017

1

Evangelia Razis

1 reference

26 July 2017

7

Epaminontas Samantas

1 reference

26 July 2017

4

Dimosthenis V Skarlos

1 reference

26 July 2017

6

Ioannis Kostopoulos

1 reference

26 July 2017

15

Pavlos Papakostas

1 reference

26 July 2017

Konstantine T Kalogeras

16

object named as

Konstantine T Kalogeras

1 reference

26 July 2017

Evangelos Briasoulis

2

1 reference

26 July 2017

Dimitrios Papamichael

5

1 reference

26 July 2017

Ioannis Xanthakis

8

1 reference

26 July 2017

Eleni Galanidi

10

1 reference

26 July 2017

Maria Bai

11

1 reference

26 July 2017

Ioanna Gikonti

12

1 reference

26 July 2017

Alona Koukouma

13

1 reference

26 July 2017

Georgia Kafiri

14

1 reference

26 July 2017

Paris Kosmidis

17

1 reference

26 July 2017

language of work or name

English

0 references

publication date

13 August 2008

1 reference

26 July 2017

1 reference

26 July 2017

8

1 reference

26 July 2017

234

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-8-234

26 July 2017

0 references

cites work

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Molecular determinants of cetuximab efficacy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

14 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-8-234

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-8-234

Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527615

Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?

31 October 2018

1 reference

12 December 2020

PTEN promoter is methylated in a proportion of invasive breast cancers

1 reference

12 December 2020

Epidermal growth factor

1 reference

12 December 2020

Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-8-234

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference